Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 12

Treatment of osteonecrosis of the femoral head by core decompression and implantation of fully functional ex vivo-expanded bone marrow-derived mesenchymal stem cells: a proof-of-concept study

Authors Mardones R, Camacho D, Monsalvo F, Zulch N, Jofre C, Minguell JJ

Received 9 August 2018

Accepted for publication 12 December 2018

Published 1 March 2019 Volume 2019:12 Pages 11—16

DOI https://doi.org/10.2147/SCCAA.S181883

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Bernard Binetruy


Rodrigo Mardones,1 Daniel Camacho,1,2 Francisco Monsalvo1 Nicolás Zulch,1 Claudio Jofre,3 José J Minguell3

1Department of Orthopedics, Clínica Las Condes, Santiago, Chile; 2Department of Orthopedics, Instituto Traumatológico, Santiago, Chile; 3Centro de Terapia Regenerativa Celular, Clínica Las Condes, Santiago, Chile

Background: Based on several attributes involved in bone formation, bone marrow-resident mesenchymal stem cells (MSCs) have been employed in the treatment of patients suffering from femoral head osteonecrosis. Due to the low content of MSCs in the bone marrow, ex vivo expansion procedures are utilized to increase the cell number. Customarily, before administration of the resulting expanded cell product MSCs to the patient, its cellular identity is usually evaluated according to a set of “minimal phenotypic” markers, which are not modified by ex vivo processing. However, MSC functional (“reparative”) markers, which are severely impaired along the ex vivo expansion routine, are usually not assessed.
Patients and methods: In this proof-of-concept study, a cohort of five avascular osteonecrosis patients received an instillation of ex vivo-expanded autologous MSCs, manufactured under controlled conditions, with an aim to protect their functional (“reparative”) capacity.
Results and conclusion: Outcomes of this study confirmed the safety and effectiveness of the MSC-based therapy used. After a follow-up period (19–54 months), in all patients, the hip function was significantly improved and pain intensity markedly reduced. As a corollary, no patient required hip arthroplasty.

Keywords: avascular necrosis, femoral head, osteonecrosis, mesenchymal stem cell-based therapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]